Merck & Co. (MRK) Stock Forecast for 2025, 2026, 2027. Sell or Buy Prediction







Understanding Accounting and Bookkeeping Services for Business Success

June 10, 2025 Understanding Accounting and Bookkeeping Services for Business Success

Every successful business relies on accurate financial records. From managing cash flow to ensuring compliance with tax regulations, reliable accounting and bookkeeping services…
How much does a Turkish passport cost?

May 27, 2025 How much does a Turkish passport cost?

Turkish citizenship comes with numerous benefits. Once granted, a foreigner can enter 126 countries visa-free, enjoy high-quality healthcare and favorable tax regimes, and…
How Measurement and Mix Modeling Drive Better Business Decisions

May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions

In today’s data-driven business landscape, the ability to accurately measure and optimize marketing efforts has become a critical competitive advantage. As marketing evolves,…
Are you making these mistakes when analyzing candlestick patterns?

May 22, 2025 Are you making these mistakes when analyzing candlestick patterns?

Trading is a very popular endeavor these days, and for good reason, as it is widely accessible and allows individuals to generate additional…
Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency

April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency

What defines a successful crypto expert? The amount of money earned, the number of luxury cars and international real estate? The presence of…

Merck & Co. (MRK) Stock Forecast for 2025, 2026, 2027. Sell or Buy?

Updated: June 16, 2025 (02:05)

Sector: Healthcare

The share price of Merck & Co., Inc. (MRK) now

Latest session on the 13th of June for
Merck & Co., Inc. is negative
Trading Volume: 14550530
Open: 81.65 /  High: 82.44 /  Low: 81.45
Current value: $81.71
What analysts predict: $101.79
52-week High/Low: $131.54 / $73.31
50-Day Moving Average: $81.27 — support level today
200-Day Moving Average: $97.4 — resistance level today

Analysts predictions

Full report
This Week
Bullish Opinions: 1 (1/0/0)
Previous Week
Neutral Opinions: Na
Two Weeks Ago
Bullish Opinions: 4 (2/2/0)
Three Weeks Ago
Neutral Opinions: Na

Are you interested in Merck & Co., Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Merck & Co. stock price in 2025, 2026, 2027. How much will one Merck & Co. share be worth in 2025 - 2027?

When should I take profit in Merck & Co. stock? When should I record a loss on Merck & Co. stock? What are analysts' forecasts for Merck & Co. stock? What is the future of Merck & Co. stock? We forecast Merck & Co. stock performance using neural networks based on historical data on Merck & Co. stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Merck & Co. stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2025, 2026, 2027, and ) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Merck & Co. shares. This happens once a day.


Historical and forecast chart of Merck & Co. stock

The chart below shows the historical price of Merck & Co. stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Merck & Co. stock price can be found in the table below.

Long-term forecasts by years.

Merck & Co., Inc. Analysts predictions review

Merck's financial stability, driven by strong cash flows, consistent dividend payouts, and strategic risk management, makes it attractive to long-term investors. Its diversified pharmaceutical portfolio, led by Keytruda and vaccine innovations, positions the company for growth in lucrative markets despite concerns over patent expirations in 2028. Strategic investments, including acquisitions like Prometheus Biosciences, bolster pipeline diversification and innovative capacities. However, macroeconomic challenges such as inflation and global healthcare budget constraints may limit near-term performance and margin expansion. Overall, Merck’s strong product pipeline, cash flow generation, and adaptability provide a positive outlook with certain medium-term risks.

Merck: A Strategic Opportunity for Risk-Managed Gains

Trend: Bullish
Jun 10, 2025

Merck’s diversification of its pharmaceutical portfolio underscores its ability to mitigate revenue concentration risks while driving sustainable growth. The author highlights the company’s robust pipeline of drugs and therapies, with particular attention to breakthrough innovations such as oncology treatments, which positions Merck favorably in highly lucrative markets.

Another key factor is the company's strong cash flow profile, which enables consistent dividend payouts and supports future R&D investment. This financial stability not only enhances shareholder value but also ensures Merck’s competitive edge in an industry dependent on innovation and long-term product cycles.

Market Position and Financial Strategy: Key Drivers

Merck’s strategic use of option collars is presented as a prudent risk management technique, shielding investors from market volatility while securing upside potential. This tactical approach aligns well with Merck’s broader financial strategy, offering a compelling case for both risk-averse and growth-focused investors.

Finally, with favorable macroeconomic and regulatory conditions, the company is well positioned to capitalize on expanding healthcare demands globally. The author suggests this external environment adds a tailwind that further supports Merck’s near-term stock price stability and appreciation.


Analyst: Sungarden Investment Publishing
( Followers: 7853
Articles: 593 )

Merck's Resilience: Key Drivers for Sustained Pharma Leadership

Trend: Bullish
May 27, 2025

Merck's continued dominance in the pharmaceutical sector rests heavily on its robust product pipeline, led by its blockbuster oncology drug Keytruda. The company's aggressive investment in expanding Keytruda's label applications underscores its capacity to maintain long-term revenue growth in the face of ongoing patent expirations, positioning the drug as a critical growth anchor.

Additionally, Merck's strategic focus on vaccine development, particularly in innovative areas such as HPV and pneumococcal vaccines, highlights its adaptability in responding to evolving healthcare demands. Author [Name] emphasizes that expanding access to global vaccine markets could provide substantial upside to the company's topline performance.

Financial and Market Expansion Catalysts

Merck's strong financial position, bolstered by consistent cash flow generation, enables it to fund acquisitions and partnerships that fortify its core operations. The company’s ability to increase shareholder value through strong dividend performance and share buybacks remains a key attraction for long-term investors.

The global pipeline diversification through strategic acquisitions like Prometheus Biosciences is highlighted as a forward-looking growth driver. If successful, these deals could foster a stronger foothold in emergent therapeutic areas, helping Merck outpace its industry peers in research and innovation.


Analyst: ALLKA Research
( Followers: 2250
Articles: 73 )

Merck: High Dividend Yield Raises Interest, But Headwinds Shape Outlook

Trend: Neutral
May 23, 2025

Merck's current dividend yield nearing a 12-year high signals strong income potential for investors seeking returns in a historically resilient pharmaceutical stock. However, the implications of rising payouts stretch beyond simple yield metrics, as author **[Author’s Name]** emphasizes concerns about the sustainability of this trend over time amid potentially slowing revenue growth.

Key Factors Influencing Merck's Outlook

One prevailing concern lies in Merck's dependency on its blockbuster cancer drug, Keytruda, which accounts for a significant portion of revenue. Although Keytruda remains a strong growth driver, the looming patent expiration in 2028 raises uncertainties about long-term revenue replacement strategies, which could weigh on investor confidence.

In addition, Merck's ongoing investments in research and development provide opportunities for innovation but carry inherent risks tied to the pharmaceutical approval process and potential delays. This balance of innovation potential and execution risk is central to assessing Merck’s ability to maintain its competitive edge.

Finally, macroeconomic factors, including inflation and global healthcare budget constraints, could dampen Merck's pricing power and profitability. These broader external pressures may influence the stock’s near-term performance and complicate margin protection strategies.


Analyst: StockBros Research
( Followers: 2917
Articles: 147 )
May 22, 2025
Merck & Co.: Assessing Inventory Implications on Stock Performance
Trend: Neutral

Merck's inventory levels reveal critical insights into the company's operational efficiency and product demand trends. Elevated inventory could signal weakening demand for key products or potential supply chain challenges, both of which may exert downward pressure on near-term stock performance. The author highlights these dynamics, suggesting cautious monitoring by investors.

R&D productivity remains a core driver of Merck's valuation, as the successful development and approval of innovative drugs directly influence revenue growth and market sentiment. Emphasizing Merck's robust pipeline, the author views this as a mitigating factor that supports a positive outlook despite short-term operational concerns.

Impact of Inventory and Pipeline Dynamics on Stock Price

Market competition, particularly in Merck's oncology and vaccine segments, presents both challenges and opportunities. While growing rivalry could compress margins, effective strategies such as enhancing marketing efforts or securing pricing advantages could maintain competitive positioning. The author implies this factor will play a pivotal role in shaping Merck's valuation trajectory in the coming quarters.

Analyst: Sensor Unlimited
( Followers: 9681
Articles: 1327 )
Apr 22, 2025
Merck: A Value Play with Robust Earnings Growth and Technical Resilience
Trend: Bullish

Merck's valuation has recently entered an appealing territory, trading at a single-digit P/E ratio. This underscores its value proposition within the pharmaceutical sector, particularly as the company continues to demonstrate strong fundamental performance and operational efficiency, signaling potential upside for value-focused investors. The author's emphasis on Merck's double-digit EPS growth highlights its robust earnings trajectory. This metric not only reflects the firm's capacity for profitability but also suggests a sustained ability to generate shareholder returns in an environment marked by strong growth momentum.

Technical Support and Forward Outlook

The discussion of technical support is critical in evaluating Merck's near-term price stability, suggesting that key levels in its stock chart could act as a buffer against excessive selling pressure. By acknowledging the firm’s technical resilience, the author points to an alignment of fundamental and technical strengths, offering a compelling case for potential investors. Additionally, Merck’s sector leadership and diversified product pipeline contribute to its competitive advantage, positioning the company well against current market dynamics. With these factors, Merck appears to be favorably cushioned from broader macroeconomic risks while poised to capitalize on opportunities in its industry.

Analyst: Mike Zaccardi, CFA, CMT
( Followers: 7673
Articles: 1792 )
Apr 21, 2025
Merck & Co.: Leveraging Innovation to Strengthen Portfolio and Drive Growth
Trend: Bullish

Merck & Co. has demonstrated exceptional resilience in its product pipeline, underscoring strong capabilities in drug development and commercialization. The author highlights that specific advancements in oncology and vaccine programs could serve as growth catalysts, driving near-term revenue expansion and boosting investor sentiment.

Focus on Strategic Diversification and Competitive Positioning

Additionally, Merck's active diversification strategy, including its pursuit of acquisitions and collaborations, reflects a deliberate effort to mitigate patent loss challenges. According to the author, these moves may help the company maintain competitive positioning within a fiercely contested pharmaceutical landscape, fortifying future cash flow streams.

The emphasis on innovation and regulatory approvals remains significant for Merck's outlook, where successful launches of new therapies and expanded use of existing blockbuster products could influence stock performance positively. The author's perspective suggests that the company's ability to navigate regulatory hurdles will remain a pivotal factor in maximizing shareholder returns.

Analyst: Oskar Goyvaerts
( Followers: 147
Articles: 7 )
Mar 26, 2025
Merck & Co.: Patent Risks Threaten Long-Term Growth Amid Drug Pipeline Challenges
Trend: Bearish

Patent expirations for Merck's successful products, particularly its blockbuster oncology drug Keytruda, create significant revenue risk. The author highlights that with Keytruda expected to lose exclusivity by 2028, the company faces heightened pressure to compensate for future revenue losses, which may affect investor confidence in Merck's long-term growth potential.

Pipeline Diversification and Competitive Landscape

The company's efforts to diversify through new acquisitions and research for innovative drugs are critical but might not be sufficient to offset near-term concerns. The author points to potential competitive threats and slower-than-expected progress in certain pipelines, which could undermine Merck's ability to outperform its peers.

Additionally, macroeconomic factors such as inflation and regulatory pressures in the pharmaceutical sector could have a compounding effect on stock performance. These externalities, combined with internal challenges, suggest a cautious approach to short-term optimism regarding MRK stock.

Analyst: Edmund Ingham
( Followers: 13131
Articles: 969 )
Mar 21, 2025
Merck Stock Analysis: Pharma Leadership and Growth Potential
Trend: Bullish

Merck's steady revenue growth, powered by its blockbuster drug Keytruda, represents the cornerstone of its market strength. The author's insights emphasize that Keytruda's sustained performance not only solidifies Merck's dominance in oncology but also fuels investor confidence in long-term growth prospects.

Expansion into innovative areas such as immuno-oncology and vaccines underscores Merck's robust R&D strategy. According to the author, these initiatives position Merck as a leader in addressing unmet medical needs, potentially catalyzing future revenue streams while strengthening competitive advantages.

Assessing Strategic Partnerships and Market Position

Merck's partnerships and acquisitions play a key role in bolstering its pipeline. The author highlights that strategic collaborations enhance Merck’s ability to diversify its portfolio and reduce reliance on Keytruda, mitigating risks tied to patent expirations.

Global market exposure, particularly in emerging regions, adds to Merck's resilience against macroeconomic pressures. Diversified revenue channels, as noted in the article, ensure stable cash flow and provide a hedge against weak performance in specific geographies.

Analyst: ALLKA Research
( Followers: 1940
Articles: 67 )
Feb 26, 2025
Merck's Oncology Pipeline Drives Momentum Amid Competitive Edge
Trend: Bullish

Merck's leadership in the oncology market, particularly through its blockbuster drug Keytruda, remains a transformative driver for the company’s earnings growth. The author underscores the drug’s expanding label approvals and robust sales trajectory, which solidify its positioning as a cornerstone asset for the company. This strengthens Merck's market moat and builds investor confidence in sustained revenue growth.

Additionally, Merck's investment in research and development (R&D) reflects its commitment to maintaining a competitive advantage. The author highlights ongoing clinical trials and pipeline depth, suggesting that successful outcomes could boost future valuation and mitigate risks associated with patent expirations.

Strategic Diversification and Potential Risks

The company's strategy of diversifying its portfolio into non-oncology segments, including vaccines and animal health, provides an additional layer of revenue stability. The author views this as a prudent approach to mitigate dependence on a single drug portfolio and insulate against sector-specific volatility.

However, potential headwinds such as generic competition and regulatory challenges in global markets warrant caution. While manageable for now, these factors could dampen the stock’s momentum if left unaddressed over the medium term.

Analyst: ALLKA Research
( Followers: 1695
Articles: 62 )
Feb 26, 2025
Merck & Co.: Evaluating Growth Potential Amid Strategic Fundamentals
Trend: Bullish

Merck & Co.'s robust financial performance, driven by strong revenue growth across key pharmaceutical segments, substantiates its appeal among long-term investors. The author notes that the company’s dependence on top-selling drugs like Keytruda and Gardasil establishes a solid revenue base, but also introduces risks tied to patent expirations and competitive pressures in a maturing immunotherapy market.

Strategic R&D Investments and Market Expansion

The company’s strategic focus on research and development (R&D) positions it well to capitalize on high-growth therapeutic areas, including oncology and vaccines. However, the pace of FDA approvals and the commercialization timeline for pipeline assets remain vital determinants of sustained investor confidence and stock price momentum.

Additionally, Merck's acquisitions—such as its recent targeting of biopharmaceutical innovators—enhance its growth potential by diversifying revenue streams. This strategy supports the company’s long-term valuation but could weigh on short-term cash flows depending on acquisition-related expenses and integration efficiency.

The competitive landscape in the pharmaceutical industry remains an external challenge for Merck, particularly as competitors advance generic alternatives and biosimilars. Nevertheless, the company’s brand strength, pipeline depth, and global market reach provide a buffer against these pressures, offering a stable outlook for investors.

Analyst: Grant Gigliotti
( Followers: 4495
Articles: 173 )
Feb 05, 2025
Merck Stock Under Pressure: Evaluating Risks and Opportunities
Trend: Neutral

Merck's recent stock performance reflects several challenges, including heightened regulatory scrutiny that could weigh on its near-term outlook. Potential risks from stricter government policies on drug pricing, particularly in the U.S., remain a focal concern, as these measures could lead to margin compression and muted revenue growth for its blockbuster therapies.

Upcoming market conditions, especially within the pharmaceutical sector, indicate increased volatility driven by macroeconomic headwinds and sector rotation to defensive positions. The author highlights that investor sentiment may further weaken if macro data continues to erode, amplifying selling pressure on MRK shares.

Pipeline Strength and Competitive Landscape

Merck’s pipeline continues to show promise, with late-stage clinical trials for key drugs poised for FDA approvals, which could mitigate recent stock declines. Despite competitive pressures from both generic manufacturers and rival pharma firms, strategic acquisitions and innovative R&D initiatives underscore Merck's resilience in sustaining long-term revenue streams.

Valuation concerns linger, as the stock currently trades at higher multiples compared to its historical averages amid broader market weakness. However, the company’s strong balance sheet and consistent dividend payouts may still appeal to income-focused investors, offering a semblance of stability during market turbulence.

Analyst: Robert & Sam Kovacs
( Followers: 44584
Articles: 464 )
Feb 04, 2025
Merck's Growth Potential Bolstered by Strategic Hedging and Upgraded Forecast
Trend: Bullish

Merck's adoption of option collars reflects a tactical approach aimed at minimizing downside risk while safeguarding upside potential. This strategy, highlighted by the author, not only signifies prudent financial management but also underscores the company's awareness of broader market volatility, a factor that could influence confidence among institutional investors.

Additionally, the upgrade to a 'Buy' rating signals growing optimism about Merck's growth trajectory amidst favorable drug pipelines and potential for revenue expansion. The critical emphasis on strong research and development (R&D) capabilities further underlines the company's ability to maintain a competitive edge, which could catalyze higher stock valuation.

Strategic Factors Driving Stock Performance

The author's argument also emphasized Merck's robust cash generation ability, which is vital for sustaining dividend payouts and funding future growth initiatives. This financial strength is likely to support the stock's attractiveness among income-focused investors while providing ample resources for strategic reinvestment.

The broader pharmaceutical sector's stable outlook adds another pillar of support to Merck's positioning. While macroeconomic conditions remain a variable, the expected resilience of healthcare demand serves as a shield, limiting downside risk for the stock price in the near term.

Analyst: Sungarden Investment Publishing
( Followers: 6717
Articles: 451 )

Merck & Co is an international pharmaceutical company. Develops, manufactures and distributes vaccines and medicines. Also publishes non-commercial medical journals, reference books. In all countries except the United States and Canada, the company’s products are sold under the Merck Sharp & Dohme brand.

The company operates in 120 countries: North America, Latin America, Europe, Africa, Asia and the Middle East. Merck & Co employs 76 thousand people. For 23 years, Fortune magazine has included the company in the Fortune Global 500 – the rating of the largest corporations in the world. In 2017, Merck was ranked 246th.

The history of the company began in 1668 when Jacob Merck bought a pharmacy in Germany. 150 years later, Jacob’s great-grandson took over the family business and began mass production of drugs. At the beginning of the 20th century, Merck & Co was considered the largest producer of alkaloids: morphine, codeine and cocaine.

Official site of the company

Trending Themes in the Healthcare Sector

Merck & Co. daily forecast for a month

Date Target Pes. Opt. Vol., %
Jun 17 81.71 81.50 82.27 0.95
Jun 18 81.32 81.14 81.79 0.80
Jun 19 81.53 81.10 81.85 0.91
Jun 20 80.96 80.64 81.53 1.10
Jun 21 81.51 80.91 82.09 1.45
Jun 22 82.17 81.81 82.52 0.86
Jun 23 81.99 81.51 82.17 0.80
Jun 24 81.79 81.55 82.04 0.60
Jun 25 82.01 81.63 82.49 1.05
Jun 26 81.62 81.27 82.17 1.11
Jun 27 80.89 80.54 81.40 1.06
Jun 28 81.42 81.07 81.81 0.91
Jun 29 81.98 81.62 82.51 1.09
Jun 30 82.30 81.96 82.64 0.83
Jul 01 82.40 81.94 82.66 0.88
Jul 02 83.12 82.87 83.50 0.76
Jul 03 83.64 83.46 84.12 0.79
Jul 04 83.40 83.04 83.85 0.98
Jul 05 83.07 82.69 83.68 1.20
Jul 06 83.36 82.82 83.74 1.12
Jul 07 83.56 82.99 83.84 1.02
Jul 08 83.76 83.27 84.18 1.10
Jul 09 83.83 83.53 84.26 0.87
Jul 10 84.51 83.86 84.98 1.34
Jul 11 84.59 84.35 85.18 0.98
Jul 12 85.33 85.13 86.00 1.02
Jul 13 85.36 84.79 85.61 0.97
Jul 14 85.24 84.77 85.91 1.34
Jul 15 84.77 84.47 85.15 0.80
Jul 16 84.54 83.88 85.06 1.41

Merck & Co. Daily Price Targets


Merck & Co. Stock Forecast 06-17-2025.

Forecast target price for 06-17-2025: $81.71.
Negative dynamics for Merck & Co. shares will prevail with possible volatility of 0.943%.
Pessimistic target level: 81.50
Optimistic target level: 82.27

Merck & Co. Stock Forecast 06-18-2025.

Forecast target price for 06-18-2025: $81.32.
Negative dynamics for Merck & Co. shares will prevail with possible volatility of 0.795%.
Pessimistic target level: 81.14
Optimistic target level: 81.79

Merck & Co. Stock Forecast 06-19-2025.

Forecast target price for 06-19-2025: $81.53.
Positive dynamics for Merck & Co. shares will prevail with possible volatility of 0.906%.
Pessimistic target level: 81.10
Optimistic target level: 81.85

Merck & Co. Stock Forecast 06-20-2025.

Forecast target price for 06-20-2025: $80.96.
Negative dynamics for Merck & Co. shares will prevail with possible volatility of 1.092%.
Pessimistic target level: 80.64
Optimistic target level: 81.53

Merck & Co. Stock Forecast 06-21-2025.

Forecast target price for 06-21-2025: $81.51.
Positive dynamics for Merck & Co. shares will prevail with possible volatility of 1.430%.
Pessimistic target level: 80.91
Optimistic target level: 82.09

Merck & Co. Stock Forecast 06-22-2025.

Forecast target price for 06-22-2025: $82.17.
Positive dynamics for Merck & Co. shares will prevail with possible volatility of 0.856%.
Pessimistic target level: 81.81
Optimistic target level: 82.52

MRK (MRK) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jul. 75.43 73.13 77.18 5.24
Aug. 77.18 75.79 77.95 2.77
Sep. 76.68 75.33 77.57 2.89
Oct. 76.77 76.07 78.28 2.82
Nov. 78.00 75.85 80.16 5.37
Dec. 80.75 78.71 83.07 5.25

Merck & Co. forecast for this year


Merck & Co. Stock Prediction for Jul 2025

An downtrend is forecast for this month with an optimal target price of $75.4265. Pessimistic: $73.13. Optimistic: $77.18


Merck & Co. Stock Prediction for Aug 2025

An uptrend is forecast for this month with an optimal target price of $77.1764. Pessimistic: $75.79. Optimistic: $77.95


Merck & Co. Stock Prediction for Sep 2025

An downtrend is forecast for this month with an optimal target price of $76.6825. Pessimistic: $75.33. Optimistic: $77.57


Merck & Co. Stock Prediction for Oct 2025

An uptrend is forecast for this month with an optimal target price of $76.7745. Pessimistic: $76.07. Optimistic: $78.28


Merck & Co. Stock Prediction for Nov 2025

An uptrend is forecast for this month with an optimal target price of $78.0029. Pessimistic: $75.85. Optimistic: $80.16


Merck & Co. Stock Prediction for Dec 2025

An uptrend is forecast for this month with an optimal target price of $80.7486. Pessimistic: $78.71. Optimistic: $83.07



Merck & Co. (MRK) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 80.23 79.14 81.10 2.41
Feb 80.14 77.67 81.03 4.15
Mar 80.17 78.18 82.70 5.47
Apr 82.96 81.20 84.68 4.11
May 81.46 80.52 82.96 2.95
Jun 81.17 80.07 82.40 2.84
Jul 83.02 80.90 84.91 4.73
Aug 82.66 81.07 84.41 3.96
Sep 84.11 82.23 85.49 3.82
Oct 87.44 85.97 90.07 4.54
Nov 87.34 85.24 89.54 4.80
Dec 89.75 87.31 90.64 3.68

Merck & Co. (MRK) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 88.49 86.79 89.77 3.31
Feb 89.80 89.01 91.42 2.63
Mar 91.45 90.14 93.50 3.60
Apr 90.98 90.21 92.36 2.32
May 89.38 87.70 90.88 3.50
Jun 91.41 89.59 92.40 3.05
Jul 93.97 92.09 96.72 4.78
Aug 95.29 92.66 96.51 3.99
Sep 96.20 93.43 98.94 5.56
Oct 97.97 95.35 99.11 3.80
Nov 97.62 94.85 99.77 4.93
Dec 94.30 91.36 96.11 4.95

Merck & Co. information and performance

Merck & Co. Address

2000 GALLOPING HILL ROAD, KENILWORTH, NJ, US

Market Capitalization: 192 947 536 000 $

Market capitalization of the Merck & Co., Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of MRK shares in the company outstanding by the market price of one share.

EBITDA: 28 795 001 000 $

EBITDA of Merck & Co. is earnings before interest, income tax and depreciation of assets.

PE Ratio: 11.17

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: 0.705

Price/earnings to growth

DPS: 3.12

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: 0.0422

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: 6.88

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: 0.075
Quarterly Revenue Growth YOY: -0.016
Trailing PE: 11.17

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 8.6

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 3.419

Enterprise Value (EV) /Revenue

EV To EBITDA: 8.39

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 2511030000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Merck & Co. (MRK) stock dividend

Merck & Co. last paid dividends on 06/16/2025. The next scheduled payment will be on 07/08/2025. The amount of dividends is $3.12 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.

Last Split Factor:

Last Split Date: 01/01/1970

Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.

For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.

FAQ (Frequently Asked Questions about Merck & Co. Stock)

Should I Buy Merck & Co. Shares in 2025 year?

The maximum forecasted share price for next year is $89.75, which is $8.00 higher than the current stock price. By investing in Merck & Co. shares today for a one-year period, you could achieve a profit of 9.78%. With an investment horizon of up to two years, the target share price is $97.97. resulting in a profit of 19.85% ($16.22 per share).

Does Merck & Co. pay dividends?

No, it does not

Which economic sector do Merck & Co.'s shares belong to?

Merck & Co.'s shares belong to the "Healthcare" sector of economic.

Which other securities belong to the same sector as Merck & Co.'s shares?

You can view all the stocks that are part of the same sector as Merck & Co.'s shares in the Healthcare section.


Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.